933989-25-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-cyanopyrimidine-5-carboxylate is used as an intermediate in the production of pyrimidine-based drugs. Its unique structure allows for the development of new therapeutic agents with potential applications in treating various diseases and conditions.
Used in Agrochemical Industry:
Methyl 2-cyanopyrimidine-5-carboxylate is also used in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products that can improve crop yields and protect plants from pests and diseases.
Used in Organic Chemistry:
As a reagent in organic chemistry reactions, methyl 2-cyanopyrimidine-5-carboxylate plays a crucial role in the synthesis of various organic compounds. Its presence in these reactions can lead to the formation of new molecules with unique properties and potential applications in various fields.

Upstream product

• 38275-41-1 methyl 2-(methylthio)pyrimidine-5-carboxylate 
• 10442-39-4 tetra-n-butylammonium cyanide 
• 38275-49-9 methyl 2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 143-33-9 sodium cyanide 

Relevant academic research and scientific papers

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or

PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS

This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.